IDEXX Laboratories Inc. is on an upward trajectory, reflecting strong investor confidence.
IDEXX Laboratories Inc. (NASDAQ:IDXX) is rising today, gaining 1.39% to close at CA$525.18. This increase comes as the company continues to demonstrate solid performance in the veterinary diagnostics sector.
Investor takeaway: Investors are responding positively to IDEXX's ongoing innovations and strategic acquisitions, which are expected to enhance its market position and drive future growth.
Advertisement
IDEXX Laboratories Inc
IDXX.US
IDXX.US
IDEXX Laboratories Inc
WealthAwesomeMarket cap
$40.81B
P/E
36.4x
52W high
$769.98
52W low
$500.61
1W change
-0.08%
Beta
1.55
Analyst Price Targets
Based on 13 analysts covering IDXX · as of Oct 5, 2026
Wall Street analysts forecast IDXX stock price to rise 35.4% over the next 12 months.
Consensus
Buy3.85 / 5.00
Avg. Target
C$701.33
+35.4% Upside
Current Price
C$518.00
Last close
Analyst Breakdown (13 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on IDXX's historical volatility
30-Day Vol
22.4%
Annualized
90-Day Vol
29.0%
Annualized
Trend (90d)
-44.6%
Annualized drift
90d Mean
C$441.68
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$491.20 | C$454.62 – C$530.72 |
| 60 trading days | C$465.78 | C$417.49 – C$519.66 |
| 90 trading days | C$441.68 | C$386.27 – C$505.04 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
IDEXX's Market Cap Reaches Over $40 Billion
With a market capitalization of approximately $40.81 billion, IDEXX remains a significant player in the veterinary diagnostics industry, reflecting its strong market presence and investor confidence.
Bull case
The recent acquisition of CoVetAI positions IDEXX to improve veterinary workflow intelligence, which could help the company capture a larger market share. Additionally, expanding its diagnostic testing capabilities in the UK strengthens its competitive edge.
Bear case
Despite the positive movement, IDEXX faces challenges such as high valuation metrics, with a P/E ratio of 36.402, which could deter some value-focused investors. A slowdown in growth or market demand might impact future performance.
Strong Financial Performance
Advertisement
IDEXX Laboratories has shown robust growth in its Companion Animal Group Diagnostics segment, which has been a key driver of its recent stock performance. Investors are optimistic about the upcoming third-quarter financial results, anticipating continued strength in this area.
Strategic Acquisitions Fuel Growth
The acquisition of CoVetAI marks a significant step for IDEXX in enhancing its technological capabilities. This move is expected to streamline veterinary workflows and improve service delivery, positioning the company for sustained growth in the competitive diagnostics market.
Innovation in Diagnostic Testing
IDEXX's expansion of its Faecal Dx Antigen Testing Platform in the UK, along with the launch of a dual-species point-of-care NT-proBNP test, underscores its commitment to innovation. These advancements are likely to attract more veterinary practices, further boosting the company's revenue potential.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
